Thursday, November 3, 2022
Smita Chandran - Memorial Sloan Kettering Cancer Center
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA